Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients
NCT00571714 · University of Nebraska · NA · withdrawn · last registry update 2023-08-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of enrollment” | – | Registry record, University of Nebraska |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IFNAR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-13Also stopped (terminated): Bosnalijek D.D, EK-12 + INF beta-1a (NCT03283397)
- 2024-07-29Results posted on the registry: Gilead Sciences, Bulevirtide + Peginterferon Alfa-2a (PEG-IFN alfa) (NCT03852433)
- 2024-07-23Phase 3 first posted: AOP Orphan Pharmaceuticals AG, Ropeginterferon alfa-2b (BESREMi®) (NCT06514807)
- 2024-07-12Also stopped (withdrawn): Fred Hutchinson Cancer Center, Interferon Beta-1A (NCT05936229)
- 2024-07-03Results posted on the registry: Janssen Research & Development, LLC, JNJ-73763989 + Tenofovir disoproxil (NCT04667104)
- 2024-06-21Phase 3 first posted: PharmaEssentia, Ropeginterferon alfa-2b (NCT06468033)
- 2024-06-12Phase 3 first posted: AstraZeneca, Anifrolumab (blinded) + Anifrolumab (unblinded, open label) (NCT06455449)
- 2024-06-03Also stopped (withdrawn): Biogen, TYSABRI and AVONEX (NCT00771043)
- 2024-04-22Results posted on the registry: Food and Drug Administration (FDA), Interferon beta-1a + Interferon beta-1a (NCT04183491)
- 2024-03-06Results posted on the registry: Janssen Research & Development, LLC, JNJ-73763989 + PegIFN-alpha-2a (NCT05005507)
- 2024-03-06Also stopped (terminated): Janssen Research & Development, LLC, JNJ-73763989 + PegIFN-alpha-2a (NCT05005507)
- 2024-03-05Results posted on the registry: Janssen Research & Development, LLC, JNJ-73763989 + JNJ-56136379 (NCT04585789)
- 2024-02-28Results posted on the registry: Massachusetts General Hospital, Panobinostat + Pegylated Interferon-alpha2a (NCT02471430)
- 2023-11-30Also stopped (terminated): University of Nebraska, Betaine + Peginterferon alpha 2a (NCT00882193)
- 2023-10-12Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Anagrelide (NCT06079879)
- 2023-10-10Phase 3 first posted: BriaCell Therapeutics Corporation, SV-BR-1-GM + Cyclophosphamide (NCT06072612)
- 2023-08-29Phase 3 first posted: AstraZeneca, Anifrolumab (NCT06015737)
- 2023-08-21Phase 3 first posted: PharmaEssentia Japan K.K., P1101 + Low-dose aspirin (NCT06002490)
- 2023-08-09Also stopped (withdrawn): Baptist Health South Florida, Cemiplimab-Rwlc + PEG-IFN alfa-2a (NCT05729139)
- 2023-07-21Also stopped (terminated): Faron Pharmaceuticals Ltd, IFN beta-1a + Dexamethasone (NCT04860518)
- 2023-06-29Phase 3 first posted: AstraZeneca, Anifrolumab (blinded) + Placebo (blinded) (NCT05925803)
- 2023-06-15Also stopped (terminated): Biogen, Dimethyl Fumarate + Peginterferon Beta-1a (NCT03870763)
- 2023-06-01Also stopped (withdrawn): Biogen, Placebo + BIIB061 (NCT04079088)
- 2023-05-16Results posted on the registry: Biogen, Dimethyl Fumarate + Peginterferon Beta-1a (NCT03870763)
- 2023-04-28Phase 3 first posted: AstraZeneca, Anifrolumab + Placebo (NCT05835310)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision